Implementing High-Flow Nasal Oxygen Therapy in Medical Wards: A Scoping Review to Understand Hospital Protocols and Procedures
International Journal of Environmental Research and Public Health · 30.05.2024 · 21 (6) · 705
DOI: 10.3390/ijerph21060705 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Environmental Research and Public Health, online erschienen am 30.05.2024. Verfasst von Toby Thomas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Melbourne Medical School, University of Melbourne, Corner Grattan Street and Royal Parade, Melbourne 3010, Australia. Hauptthemen laut MEDLINE: Oxygen Inhalation Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute hypoxemic respiratory failure (ARF) is a common cause for hospital admission. High-flow nasal oxygen (HFNO) is increasingly used as a first-line treatment for patients with ARF, including in medical wards. Clinical guidance is crucial when providing HFNO, and health services use local health guidance documents (LHGDs) to achieve this. It is unknown what hospital LHGDs recommend regarding ward administration of HFNO. This study examined Australian hospitals’ LHGDs regarding ward-based HFNO administration to determine content that may affect safe delivery. A scoping review was undertaken on 2 May 2022 and updated on 29 January 2024 to identify public hospitals’ LHGDs regarding delivery of HFNO to adults with ARF in medical wards in two Australian states. Data were extracted and analysed regarding HFNO initiation, monitoring, maintenance and weaning, and management of clinical deterioration. Of the twenty-six included LHGDs, five documents referenced Australian Oxygen Guidelines. Twenty LHGDs did not define a threshold level of hypoxaemia where HFNO use was recommended over conventional oxygen therapy. Thirteen did not provide target oxygen saturation ranges whilst utilising HFNO. Recommendations varied regarding maximal levels of inspired oxygen and flow rates in the medical ward. Eight LHGDs did not specify any system to identify and manage deteriorating patients. Five LHGDs did not provide guidance for weaning patients from HFNO. There was substantial variation in the LHGDs regarding HFNO care for adult patients with ARF in Australian hospitals. These findings have implications for the delivery of high-quality, safe clinical care in hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melbourne Medical School, University of Melbourne, Corner Grattan Street and Royal Parade, Melbourne 3010, Australia.
- Respiratory Research @Alfred, School of Translational Medicine, The Alfred Centre, Monash University, Melbourne 3004, Australia.
- Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg 3084, Australia.
- Institute for Breathing and Sleep, Heidelberg 3084, Australia.
ORCID-Profile: Toby Thomas, Yet Hong Khor, Catherine Buchan, Natasha Smallwood
Zitieren
APA
Thomas, T., Khor, Y. H., Buchan, C., & Smallwood, N. (2024). Implementing High-Flow Nasal Oxygen Therapy in Medical Wards: A Scoping Review to Understand Hospital Protocols and Procedures. International Journal of Environmental Research and Public Health, 21(6), 705. https://doi.org/10.3390/ijerph21060705
Vancouver
Thomas T, Khor YH, Buchan C, Smallwood N. Implementing High-Flow Nasal Oxygen Therapy in Medical Wards: A Scoping Review to Understand Hospital Protocols and Procedures. International Journal of Environmental Research and Public Health. 2024;21(6):705. doi:10.3390/ijerph21060705
BibTeX
@article{Thomas2024,
author = {Thomas, Toby and Khor, Yet Hong and Buchan, Catherine and Smallwood, Natasha},
title = {Implementing High-Flow Nasal Oxygen Therapy in Medical Wards: A Scoping Review to Understand Hospital Protocols and Procedures},
journal = {International Journal of Environmental Research and Public Health},
year = {2024},
volume = {21},
number = {6},
pages = {705},
doi = {10.3390/ijerph21060705}
}
EUVIMED